Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oncology Institute (TOI) EBT (2020 - 2025)

Oncology Institute's EBT history spans 6 years, with the latest figure at -$7.5 million for Q4 2025.

  • For Q4 2025, EBT rose 43.04% year-over-year to -$7.5 million; the TTM value through Dec 2025 reached -$60.7 million, up 6.07%, while the annual FY2025 figure was -$60.7 million, 6.07% up from the prior year.
  • EBT reached -$7.5 million in Q4 2025 per TOI's latest filing, up from -$16.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $19.5 million in Q1 2022 to a low of -$30.0 million in Q1 2023.
  • Average EBT over 5 years is -$11.0 million, with a median of -$14.3 million recorded in 2024.
  • Peak YoY movement for EBT: skyrocketed 2602.06% in 2022, then plummeted 540.62% in 2023.
  • A 5-year view of EBT shows it stood at -$12.6 million in 2021, then grew by 9.9% to -$11.4 million in 2022, then crashed by 67.65% to -$19.1 million in 2023, then skyrocketed by 30.87% to -$13.2 million in 2024, then soared by 43.04% to -$7.5 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's EBT are -$7.5 million (Q4 2025), -$16.5 million (Q3 2025), and -$17.1 million (Q2 2025).